Jarl Ulf Jungnelius, Md, Phd

Biography

 Jarl Ulf Jungnelius, MD, PhD worked at Celgene from 2007 to 2014 where he served as Vice President of Clinical Research and Development, Solid Tumors. Prior to that post Dr. Jungnelius held leadership positions at Takeda, Pfizer and Eli Lilly & Company, where he was responsible for clinical development of oncology programs as well as involved in business development. Dr. Jungnelius held important responsibilities in the clinical development of several successful oncology drugs, including Abraxane®, Gemzar®, Alimta® and Revlimid®. He is an oncologist with more than 25 years of clinical and research experience at both large pharmaceutical companies and academic organizations. Dr. Jungnelius is currently Chief Medical Officer at VAXIMM, Supervisory Board director of Isofol Medical AB, Biovica International AB and Monocl AB and has been a director at Oncopeptides AB since April 2011. He received both a Bachelor of Science degree and his MD from the Karolinska Institute in Stockholm Sweden.

Research Interest

 oncopedics